HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT

Clinical trials for HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT explained in plain language.

Never miss a new study

Get alerted when new HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT trials appear

Sign up with your email to follow new studies for HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for sickle cell cure: drug may prevent transplant failure

⭐️ CURE ⭐️ Not yet recruiting

This study is testing if adding a drug called ruxolitinib to a stem cell transplant can help prevent the body from rejecting the new cells, which is a major risk. It aims to improve the chance of a cure for children and young adults with severe sickle cell disease. Up to 24 parti…

Matched conditions: HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT

Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: ⭐️ CURE ⭐️

Last updated Mar 12, 2026 13:50 UTC

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT

Get alerted when new HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT trials appear

New hope for sickle cell cure: drug may prevent transplant failure